



NDA16-517/S-09

SUPPLEMENT APPROVAL

Mallinckrodt Inc.
Attention: Janice Karibian
Regulatory Affairs Associate
675 McDonnell Boulevard
P.O. 5840
St. Louis, MO 63134

Dear Ms. Karibian:

Please refer to your Supplemental New Drug Application (sNDA) dated October 7, 2005, received October 11, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Sodium Iodide I-131 Therapeutic Capsules.

We acknowledge receipt of your amendments dated March 4 and 17, 2006, February 22, 2008, August 4, 2011, December 1, 2011, and January 27, 2012. The August 4, 2011, submission constituted a complete response to our August 4, 2010, action letter.

This "Prior Approval" supplemental new drug application proposes a labeling change to the package insert to add adverse event information described in the scientific literature as well as a labeling PLR conversion.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert, with the addition of any labeling changes in pending "Changes Being Effectuated" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Frank Lutterodt, Regulatory Project Manager, at (301) 796-4251.

Sincerely,

{See appended electronic signature page}

Rafel Dwaine Rieves, M.D.
Director
Division of Medical Imaging Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURE:

Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RAFEL D RIEVES
02/03/2012